Oncobiologics Company Profile (NASDAQ:ONSIU)

About Oncobiologics (NASDAQ:ONSIU)

Oncobiologics logoOncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONSIU
  • CUSIP: N/A
  • Web: oncobiologics.com/
Average Prices:
  • 50 Day Moving Avg: $5.09
  • 200 Day Moving Avg: $5.09
  • 52 Week Range: $4.56 - $5.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.02
  • P/E Growth: 0.00
  • Net Margins: -1,695.08%
  • Average Volume: 47,447 shs.
Frequently Asked Questions for Oncobiologics (NASDAQ:ONSIU)

What is Oncobiologics' stock symbol?

Oncobiologics trades on the NASDAQ under the ticker symbol "ONSIU."

Who are some of Oncobiologics' key competitors?

Who are Oncobiologics' key executives?

Oncobiologics' management team includes the folowing people:

  • Pankaj Mohan Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Lawrence A. Kenyon, Chief Financial Officer, Secretary
  • Scott Gangloff, Senior Vice President - Process Development and Manufacturing
  • Stephen J. McAndrew Ph.D., Senior Vice President - Business Strategy & Development
  • Kenneth M. Bahrt M.D., Chief Medical Officer

When did Oncobiologics IPO?

(ONSIU) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

How do I buy Oncobiologics stock?

Shares of Oncobiologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncobiologics' stock price today?

One share of Oncobiologics stock can currently be purchased for approximately $4.62.

MarketBeat Community Rating for Oncobiologics (NASDAQ ONSIU)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Oncobiologics (NASDAQ:ONSIU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Oncobiologics (NASDAQ:ONSIU)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/7/2017Jefferies Group LLCDowngradeBuy -> HoldN/AView Rating Details
6/7/2016Cantor FitzgeraldInitiated CoverageBuy$15.00N/AView Rating Details
6/7/2016Barclays PLCInitiated CoverageOverweight$11.00N/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for Oncobiologics (NASDAQ:ONSIU)
No earnings announcements for this company have been tracked by MarketBeat.com


Earnings Estimates for Oncobiologics (NASDAQ:ONSIU)
Current Year EPS Consensus Estimate: $-2.56 EPS
Next Year EPS Consensus Estimate: $-2.29 EPS


Dividend History for Oncobiologics (NASDAQ:ONSIU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oncobiologics (NASDAQ:ONSIU)
No insider trades for this company have been tracked by MarketBeat.com


Headline Trends for Oncobiologics (NASDAQ:ONSIU)
Latest Headlines for Oncobiologics (NASDAQ:ONSIU)



Oncobiologics (ONSIU) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff